By continuing to use this site, you consent to our use of cookies to personalize your experience and to analyze website traffic. Learn more in our Privacy Policy.

Accept
Privacy Policy

See RELiZORB real-world results #

#
Upcoming Educational Programs
#

Equip your patients to improve fat absorption and tube-feeding tolerance and get more from their enteral nutrition1

RELiZORB is indicated for use in pediatric (including neonates and infants) and adult patients to hydrolyze fats during enteral feeding.1

Close up of the RELiZORB redesigned cartridge

Introduction

Learn more about RELiZORB

Hear from actual RELiZORB patients

RELiZORB hydrolyzes fats prior to ingestion1

RELiZORB is a digestive enzyme cartridge that connects in-line to a variety of enteral nutrition setups to ease the burden of the fat-digestion process for your tube-fed patients experiencing fat malabsorption.

RELiZORB (iMMOBILIZED LIPASE) CARTRIDGE

Designed to mimic the function of the digestive pancreatic enzyme lipase, RELiZORB contains the lipase-bead complex iLipase® (iMMOBILIZED lipase) between 2 filters to hydrolyze fats as enteral nutrition flows through.1

See how RELiZORB works

Video thumbnail featuring Sivan Kinberg, MD, and her patient Caleb, and his caregiver discussing collaborative care with RELiZORB

Caleb’s Story: Collaborative Care

See how shared decision-making between your peer, Sivan Kinberg, MD, and her patient’s caregiver led to a favorable outcome for her patient, Caleb, using RELiZORB

Hear from more of your peers

RELiZORB is proven to hydrolyze available fats, including medium-chain triglycerides (MCTs) and long-chain triglycerides (LCTs)1,2

  • LCTs are complex and contain essential fatty acids
  • Compared to MCTs, LCTs are harder to hydrolyze but provide ~10% more calories

RELiZORB provides continuous fat hydrolysis throughout the entire feed1

Explore clinical and preclinical results

See a demonstration of using RELiZORB with Sivan Kinberg, MD

RELiZORB is compatible with a wide variety of tube-feeding setups. Find out exactly how RELiZORB can fit your patient’s setup from your peer Sivan Kinberg, MD.1

Watch the video

Portrait of Sivan Kinberg, MD, pediatric gastroenterologist

Sivan Kinberg, MD, pediatric gastroenterology

Photo of Caleb, who uses RELiZORB, playing with his father, Jimmy

Real-life patient Caleb, who uses RELiZORB with his tube feeds, and his father, Jimmy

Explore valuable resources for you and your practice

Discover practice resources

#

References: 1. RELiZORB. Instructions for use. Alcresta Therapeutics, Inc; 2025. 2. Shah ND, Limketkai BN. The use of medium-chain triglycerides in gastrointestinal disorders. Practical Gastroenterol. 2017;41(2):20-28.

RELiZORB is indicated for use in pediatric (including neonates and infants) and adult patients to hydrolyze fats during enteral feeding.

Warnings
  • RELiZORB is for use with enteral tube feeding only.
See more
#

RELiZORB is indicated for use in pediatric (including neonates and infants) and adult patients to hydrolyze fats during enteral feeding.

Warnings
  • RELiZORB is for use with enteral tube feeding only.
  • RELiZORB should not be connected to any intravenous (IV) line, setup, or system.
  • Medications should not be administered through the RELiZORB cartridge. Do not add medications to the enteral nutrition or tubing before RELiZORB. The passage of medications through RELiZORB may adversely affect the medications or the ability of RELiZORB to hydrolyze fats.
  • Fibrosing Colonopathy - Fibrosing colonopathy is a rare, serious adverse reaction associated with high-dose use of pancreatic enzyme replacement therapy in the treatment of patients with cystic fibrosis. The underlying mechanism of fibrosing colonopathy remains unknown. Patients with fibrosing colonopathy should be closely monitored because some patients may be at risk of progressing to stricture formation. RELiZORB contains lipase enzyme that is not from a porcine source. The lipase is bound to the beads, and this lipase-bead complex (iLipase) is retained within the RELiZORB cartridge. Continue to follow your physician’s guidance and porcine pancreatic enzyme labeling regarding porcine pancreatic enzyme use when used in conjunction with RELiZORB.
Cautions and Precautions
  • Do not re-use RELiZORB. RELiZORB is a single-use product. Re-use may result in contamination of the product. If re-used, RELiZORB may not effectively hydrolyze fats.
  • Do not break, alter, or place excess pressure on any part of RELiZORB. Any compromise of the structural integrity of RELiZORB may lead to improper connection to enteral feeding supplies, leakage or risk of contamination.
  • Do not use RELiZORB after the date marked on the pouch.
  • Enteral nutrition administered through RELiZORB is for immediate consumption through an enteral feeding tube. RELiZORB should not be used to process enteral nutrition for later use. This has not been tested and may result in safety issues.
  • RELiZORB is designed for use with enteral feeding pump systems with low flow/no flow alarms and enteral syringes for manual bolus by syringe (push or gravity). A detailed listing of enteral nutrition, pumps, and enteral feeding supplies compatible with RELiZORB can be found at www.relizorbhcp.com/compatibility.
  • Patients less than 1 year old may be particularly vulnerable to unplanned interruptions of feeding.
  • Do not use blenderized formulas with RELiZORB. A detailed listing of enteral nutrition compatible with RELiZORB can be found at www.relizorbhcp.com/compatibility.
  • Powdered formulas should be mixed periodically during feedings.
  • Do not use excessive force on the plunger when using RELiZORB with bolus syringe feeding method.
  • Do not rush bolus feeds. Follow guidance from your healthcare professional on how long it should take you to complete your tube feeding. Ensure all inlet and outlet connectors on RELiZORB and enteral feeding supplies are clean and dry prior to making connections.
  • In order to ensure product performance, store RELiZORB in its pouch either refrigerated or at room temperature (2°C to 27°C; 36°F to 80°F).
  • RELiZORB is indicated for use with enteral feeding only; patients should follow physician’s guidance for pancreatic enzyme replacement therapy (PERT) use for meals and snacks. Patients and patient caregivers should follow physician’s guidance regarding the need for pancreatic enzyme replacement therapy (PERT) during enteral feeding.

Review full product information for RELiZORB in the Instructions for Use.